Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Adenoma, Islet Cell × Radiofrequency Ablation × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Thyroid Nodule 2 Thyroid Neoplasms 1 Recurrence 1 Pancreatic Neuroendocrine Tumors, WHO Grade I-II 1 Neuroma 1 Neuralgia 1 Liver Metastasis Colon Cancer 1 Klatskin Tumor 1 Kidney Neoplasms 1 Hypesthesia 1 Esophageal Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Bone Cancer Metastatic 1 Bile Duct Neoplasms 1 Agnosia 1 Adrenocortical Adenoma 1 Adenoma, Islet Cell 1

Interventions

Everolimus 3 lutetium Lu 177 dotatate 2 Sunitinib 2 Specimen Handling 2 Magnetic Resonance Spectroscopy 2 lanreotide 1 fludarabine phosphate 1 belzutifan 1 Temozolomide 1 Sorafenib 1 Radiofrequency Ablation 1 Octreotide 1 Interleukin-13 1 Histocompatibility Testing 1 Gefitinib 1 Fulvestrant 1 Fluorodeoxyglucose F18 1 Cytoreduction Surgical Procedures 1 Cyclophosphamide 1 Capecitabine 1 Blood Specimen Collection 1 Biopsy 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04520932 2025-05-25

RFANET

Institut Paoli-Calmettes

Phase NA Recruiting

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡